Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US

August 30, 2021 Auto Bot Bio-Thera, Biosimilar, Biosimilars, Commercialization, Hikma, License Agreement, ustekinumab 0

Shots:

  • Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development, manufacturing, and supply of BAT2206
  • Hikma get exclusive rights to commercialize the biosimilar in the US and received first-right-to-negotiate to add Europe (excluding CIS countries)
  • BAT2206 is a mAb, that is a proposed biosimilar referencing Janssen’s Stelara (ustekinumab) and is currently in a global P-III clinical trial

Click here to­ read full press release/ article | Ref: Businesswire | Image: Hikma

The post Bio-Thera and Hikma Sign an Exclusive Commercialization and License Agreement for BAT2206 (biosimilar, ustekinumab) in the US first appeared on PharmaShots.